Literature DB >> 32195120

Advances in medicine and positive natural selection: Prosthetic valve endocarditis due to biofilm producer Micrococcus luteus.

Guillermo Rodriguez-Nava1, Abdelnasir Mohamed1, Maria Adriana Yanez-Bello1, Daniela Patricia Trelles-Garcia1.   

Abstract

Over the past years there has been a considerable increase in the use of aortic bioprostheses for treating aortic valve disease. With the increasing use of implanted medical devices, the incidence of prosthetic valve endocarditis has also increased. This is accompanied by a shift in the microbiology of infectious endocarditis. Micrococcus species are usually regarded as contaminants from skin and mucous membranes that rarely cause infectious diseases, however, they have the capacity to create biofilms from prosthetic materials and hence, to cause disease. We report the case of a 54-year-old woman who developed native valve infective endocarditis due to Micrococcus luteus. To our knowledge, only 18 cases of M. luteus prosthetic valve endocarditis have been described, none in the English literature.
© 2020 The Authors.

Entities:  

Keywords:  Aortic valve; Biofilm; Infective endocarditis; Prosthetic valve

Year:  2020        PMID: 32195120      PMCID: PMC7076149          DOI: 10.1016/j.idcr.2020.e00743

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

In recent times, there has been a considerable increase in the use of aortic bioprostheses for treating aortic valve disease, and this tendency is likely to continue in the near future. Worldwide, more than 200,000 surgical aortic valve replacements are performed each year [1]. Prosthetic valve endocarditis (PVE) is associated with high mortality and its incidence has increased over the past years, mainly due to the increasing use of implanted medical devices. Staphylococcus aureus and coagulase-negative staphylococcus are the most common microorganisms associated with PVE [2]. Micrococcus species are usually regarded as contaminants from skin and mucous membranes that rarely cause infectious diseases such as bacteremia, endocarditis, pneumonia and septic arthritis [3]. Micrococcus luteus is a rare cause of infective prosthetic valve endocarditis. To our knowledge, only 18 cases of M. luteus prosthetic valve endocarditis have been described, none in the English literature [4,5].

Case description

A 54-year old female was brought to the hospital after an unwitnessed fall and fever. Past medical history was relevant for an aortic valve replacement with bioprosthetic valve complicated by complete heart block requiring permanent pacemaker placement five years before presentation. On admission, she was found with a temperature of 39.6 C, a heart rate of 100 bpm and leukocytosis 27.4 k/mm3. Physical exam was unremarkable, except for a holosystolic murmur best audible over sternal border bilaterally and chronic venous insufficiency in lower extremities. Initial laboratories showed a procalcitonin of 23.9 ng/mL and a CRP of 12.1 mg/dL. Urinalysis did not show signs of infection, chest x-rays were negative for consolidations, and a viral panel was negative for respiratory viruses including RSV and influenza. She was started on broad-spectrum antibiotics: vancomycin and meropenem. Subsequently, blood cultures grew Micrococcus luteus, which was considered a skin contaminant at that point. However, after 5 days of broad-spectrum antibiotics, fever persisted. Given the presence of fever, positive blood cultures and a systolic murmur, infective endocarditis due to M. luteus was suspected. A transesophageal echocardiogram was performed, demonstrating small vegetation attached to the posterior leaflet. The patient was started on vancomycin 1750 mg every 24 h and rifampin 600 mg every 24 h. Her condition improved within the first few days, she became afebrile and white blood cell count improved. Follow-up blood cultures were negative. She received a course of 8 weeks of vancomycin and rifampicin. Regular clinical follow-up was normal.

Discussion

Prosthetic valves account for up to 34 % of all cases of infective endocarditis and it is accompanied by hospital mortality as high as 50 %. The microbiology of PVE is very different from native valve endocarditis (NVE), moreover, the microbiology of early-onset PVE (<2 months), intermediate-onset PVE (2–12 months) and late-onset PVE (>12 months) are also different. In the report by Lee [6] the most frequent infecting organisms after 1 year were Staphylococcus aureus (30 %), nonenterococcal streptococci (25 %, with 16 % viridans), coagulase-negative staphylococcus (13 %) and Enterococcus (10 %). Micrococcus species, members of the family Micrococcaceae, are gram-positive cocci, catalase-positive, arranged in tetrad clusters. They can be differentiated from Staphylococcus due to their inability to produce acid from glucose in anaerobiosis, their resistance to lysostaphin and furazolidone, their sensibility to bacitracin, and positive modified oxidase test [5]. M. luteus is commonly regarded as a contaminant from the skin and mucous membranes [3]. Although of low virulence, it has been previously documented as a pathogen capable to colonize prosthetic valves and native valves in immunocompromised patients [7,8,10]. Micrococcus species have the capability to form biofilms with a prosthetic material, which could explain why most of the reported cases are with prosthetic valves [8]. In biofilms, cells grow in multicellular aggregates that are encased in an extracellular matrix produced by the bacteria. Formation of biofilms on medical devices often results in difficult-to-treat infections, mainly due to the numerous benefits that a bacterial community might obtain from the formation of biofilms including resistance to antibiotics, protection from protozoan grazing, and protection against host defenses [9]. There is no defined therapeutic regimen for infective endocarditis. In contrast to staphylococci, it is usually penicillin-sensitive and also has been reported to be susceptible to aminoglycosides, clindamycin, tetracycline, ofloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, rifampin, and fusidic acid [3,11]. Most of the previously reported cases, including this case, were successfully treated with a combination of vancomycin and rifampin. This regimen was selected based on documented susceptibilities and the ability of rifampin and vancomycin to penetrate biofilms [12,13]. This case exemplifies how human activity (in this context advances in medicine and the increasing use of bioprosthetic medical devices) influences our Milieu intérieur and has an impact on evolutionary adaptation and positive natural selection, favoring that bacteria that are not usually pathogenic, such as Micrococcus luteus, are now more fit to cause disease in immunocompetent patients.

Informed consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request

Author contribution

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication.

Ethical approval

Our institution does not require ethical approval for case reports

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Guillermo Rodriguez-Nava: Conceptualization, Writing - original draft, Writing - review & editing. Abdelnasir Mohamed: Conceptualization, Writing - review & editing. Maria Adriana Yanez-Bello: Writing - review & editing. Daniela Patricia Trelles-Garcia: Writing - review & editing.

Declaration of Competing Interest

No conflict of interest was declared by the authors.
  13 in total

Review 1.  [Endocarditis due to Micrococcus luteus].

Authors:  Jordi Usó; María Gil; Bárbara Gomila; M Dolores Tirado
Journal:  Enferm Infecc Microbiol Clin       Date:  2003-02       Impact factor: 1.731

Review 2.  Biofilms.

Authors:  Daniel López; Hera Vlamakis; Roberto Kolter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-02       Impact factor: 10.005

Review 3.  Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration.

Authors:  Tania Rodriguez-Gabella; Pierre Voisine; Rishi Puri; Philippe Pibarot; Josep Rodés-Cabau
Journal:  J Am Coll Cardiol       Date:  2017-08-22       Impact factor: 24.094

4.  Penetration of rifampin through Staphylococcus epidermidis biofilms.

Authors:  Zhilan Zheng; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  [Micrococcus luteus: a rare pathogen of valve prosthesis endocarditis].

Authors:  U N Dürst; E Bruder; L Egloff; J Wüst; J Schneider; H O Hirzel
Journal:  Z Kardiol       Date:  1991-04

6.  Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria.

Authors:  R O Darouiche; A Dhir; A J Miller; G C Landon; I I Raad; D M Musher
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

Review 7.  Micrococcus luteus endocarditis: case report and review of the literature.

Authors:  H Seifert; M Kaltheuner; F Perdreau-Remington
Journal:  Zentralbl Bakteriol       Date:  1995-10

8.  Enterococcal prosthetic valve endocarditis secondary to transurethral prostatic resection.

Authors:  Yasmin Moussa; Mohamed Moussa; Mohamed Abou Chakra
Journal:  IDCases       Date:  2020-01-29

9.  The First Case of Native Mitral Valve Endocarditis due to Micrococcus luteus and Review of the Literature.

Authors:  Alisha Khan; Thu Thu Aung; Debanik Chaudhuri
Journal:  Case Rep Cardiol       Date:  2019-12-04

10.  Native valve infective endocarditis due to Micrococcus luteus in a non-Hodgkin's lymphoma patient.

Authors:  Nicole M Ianniello; Diana C Andrade; Stipe Ivancic; Paula A Eckardt; Juan C Lemos Ramirez
Journal:  IDCases       Date:  2019-10-14
View more
  3 in total

Review 1.  Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis.

Authors:  Qi Tong; Tao Li; Lu Jiang; Zhengjie Wang; Yongjun Qian
Journal:  Anatol J Cardiol       Date:  2022-02       Impact factor: 1.596

2.  Comparative genomics reveals broad genetic diversity, extensive recombination and nascent ecological adaptation in Micrococcus luteus.

Authors:  Yisong Li; Zhong-Zhi Sun; Jin-Cheng Rong; Bin-Bin Xie
Journal:  BMC Genomics       Date:  2021-02-18       Impact factor: 3.969

3.  Characterizing the microbiota of instrumentation in ophthalmology clinics during and beyond the COVID-19 pandemic.

Authors:  Heba Mahjoub; Sean X Zhang; Jiangxia Wang; Warda Memon; Heba Mostafa; Mark P Breazzano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-31       Impact factor: 3.535

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.